253 related articles for article (PubMed ID: 31413568)
1. Targeted delivery of doxorubicin to HER2 positive tumor models.
Gomari H; Forouzandeh Moghadam M; Soleimani M; Ghavami M; Khodashenas S
Int J Nanomedicine; 2019; 14():5679-5690. PubMed ID: 31413568
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle.
Gomari H; Forouzandeh Moghadam M; Soleimani M
Onco Targets Ther; 2018; 11():5753-5762. PubMed ID: 30254468
[TBL] [Abstract][Full Text] [Related]
3. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
4. Exosome mimetics derived from bone marrow mesenchymal stem cells ablate neuroblastoma tumor in vitro and in vivo.
Li M; Wang J; Guo P; Jin L; Tan X; Zhang Z; Zhanghuang C; Mi T; Liu J; Wang Z; Wu X; Wei G; He D
Biomater Adv; 2022 Nov; 142():213161. PubMed ID: 36308859
[TBL] [Abstract][Full Text] [Related]
5. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
6. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.
Tian Y; Li S; Song J; Ji T; Zhu M; Anderson GJ; Wei J; Nie G
Biomaterials; 2014 Feb; 35(7):2383-90. PubMed ID: 24345736
[TBL] [Abstract][Full Text] [Related]
7. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.
Barok M; Puhka M; Vereb G; Szollosi J; Isola J; Joensuu H
BMC Cancer; 2018 May; 18(1):504. PubMed ID: 29720111
[TBL] [Abstract][Full Text] [Related]
8. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
9. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer.
Hosseini NF; Amini R; Ramezani M; Saidijam M; Hashemi SM; Najafi R
Biomed Pharmacother; 2022 Nov; 155():113690. PubMed ID: 36099793
[TBL] [Abstract][Full Text] [Related]
10. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
Liang G; Zhu Y; Ali DJ; Tian T; Xu H; Si K; Sun B; Chen B; Xiao Z
J Nanobiotechnology; 2020 Jan; 18(1):10. PubMed ID: 31918721
[TBL] [Abstract][Full Text] [Related]
11. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
12. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium.
Wan Z; Zhao L; Lu F; Gao X; Dong Y; Zhao Y; Wei M; Yang G; Xing C; Liu L
Theranostics; 2020; 10(1):218-230. PubMed ID: 31903116
[No Abstract] [Full Text] [Related]
13. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
[TBL] [Abstract][Full Text] [Related]
15. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
[TBL] [Abstract][Full Text] [Related]
16. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo.
Naseri Z; Oskuee RK; Jaafari MR; Forouzandeh Moghadam M
Int J Nanomedicine; 2018; 13():7727-7747. PubMed ID: 30538455
[TBL] [Abstract][Full Text] [Related]
17. Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells.
Limoni SK; Moghadam MF; Moazzeni SM; Gomari H; Salimi F
Appl Biochem Biotechnol; 2019 Jan; 187(1):352-364. PubMed ID: 29951961
[TBL] [Abstract][Full Text] [Related]
18. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
19. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
20. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
